



5 March 2021

Sydney, Australia

Appendix 3Y Change of Director's Interest Notice

Sydney, 5 March 2021: Nyrada Inc (ASX: NYR), a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today released an Appendix 3Y for its Chair, Mr Moore.

The Appendix 3Y contains notification of an acquisition of 19,000 Chess Depository Interests ("CDIs") by Mr Moore on 2 March 2021.

As part of the Company's internal process to periodically review its records, it has come to the attention of the Company that there was a typographic error in the documentation upon which the prior Appendix 3Y (lodged on 26 November 2020) of Mr Moore was prepared ("Historic Appendix 3Y"). The Historic Appendix 3Y confirmed an acquisition on 25 November 2020 of 32,000 CDIs, whereas the actual transaction was for 32,500 CDIs.

This has been noted and corrected in the Appendix 3Y released today.

The Company's Continuous Disclosure Policy is designed to ensure compliance with ASX Listing rules disclosure. Each Director understands the requirements to disclose their interests within the prescribed time and the Company has undertaken a review of its governance and compliance practices and is confident that the Company's ongoing reporting obligations will continue to be complied with in a timely manner.

The Appendix 3Y for Mr Moore is attached.

Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:

Laura Vize
Investor Relations Manager
T: 0417 026 056
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com



Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/

Name of entity	Nyrada Inc
ARBN	625 401 818

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Moore
Date of last notice	26 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	2 March 2021
No. of securities held prior to change	<p><u>DIRECT</u></p> <ol style="list-style-type: none"> 1. 262,000 Chess Depositary Interests 2. 3,600,000 <u>Unlisted</u> Employee Share Option Plan options (24-month escrow from IPO date), comprising: <ul style="list-style-type: none"> • 1,200,000 options will vest upon the first anniversary of the grant date of 16 January 2020 (the Exercise price is 120% of the Offer Price (Offer price \$0.20), Expiry 3 years from the date on which the option vests); • 1,200,000 options will vest upon the second anniversary of the grant date of 16 January 2020 (Expiry 3 years from the date on which the option vests); and • 1,200,000 options will vest upon the third anniversary of the grant date of 16

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

	January 2020 (Expiry 3 years from the date on which the option vests).
Class	Chess Depositary Interests
Number acquired	<ol style="list-style-type: none"> 1. 500 Chess Depositary Interests 2. 19,000 Chess Depositary Interests
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> 1. 500 shares at \$0.205 (Total: \$102.50) - typographic error on form lodged 26 November 2020 2. 19,000 shares at \$0.35 (Total: \$6,650.00)
No. of securities held after change	<p><u>DIRECT</u></p> <ol style="list-style-type: none"> 1. 281,500 Chess Depositary Interests 2. 3,600,000 <u>Unlisted</u> Employee Share Option Plan options (24-month escrow from IPO date), comprising: <ul style="list-style-type: none"> • 1,200,000 options will vest upon the first anniversary of the grant date of 16 January 2020 (the Exercise price is 120% of the Offer Price (Offer price \$0.20), Expiry 3 years from the date on which the option vests); • 1,200,000 options will vest upon the second anniversary of the grant date of 16 January 2020 (Expiry 3 years from the date on which the option vests); and • 1,200,000 options will vest upon the third anniversary of the grant date of 16 January 2020 (Expiry 3 years from the date on which the option vests).
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> 1. Correction of typographic error on form lodged 26 November 2020 2. On-Market Trade

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.